CD274 and neoplasm: Among HER2 ex20ins patients, 9/47 (19%) had tumours with PD-L1 greater or equal to 50%, 10/47 (11%) had 1–49% PD-L1, and 23/47 (49%) had PD-L1 > 50% (Table 3C).